Friday, March 31, 2017 6:05:31 AM
Genetic Technologies Revamps Patient Pricing and Billing Program for BREVAGenplus®
MELBOURNE, AUSTRALIA--(Marketwired - Mar 31, 2017) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company focused on cancer risk assessment, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, announced today a change to the product's pricing and billing structure. Effective 1 April 2017, the Company will transition from a traditional reimbursement system through insurance providers, to a direct patient self-pay program.
The rationale behind this strategic shift is based on the recognition that gaining adequate payment for BREVAGenplus has become increasingly difficult over the last few years using a traditional payment model. The Company is not alone in this respect, as it is an acknowledged issue for those companies selling molecular diagnostics (MDx) and seeking reimbursement from insurers through a Current Procedural Terminology (CPT) miscellaneous code. The primary issue is that current regulations/laws leave patients with minimum, if any, definition on how much they will be required to pay out of pocket for BREVAGenplus. Ultimately, this lack of fundamental transparency often demotivates patients' and physicians' interest in BREVAGenplus and furthermore, makes the collection of monies for services rendered more difficult. By converting to a direct pay relationship with patients, the Company aims to add certainty to the transaction. This will eliminate current issues being experienced, such as low levels of reimbursement, prolonged payment time, patient confusion around eligibility and financial responsibility, poor coverage, and the need for multiple laboratory locations.
"We are excited to implement this streamlined payment system as it dramatically simplifies the cost side of the equation for patients and makes it easy for physicians and their staff to answer questions regarding cost before sample collection. Additionally, transitioning to a direct patient self-pay program provides us with a defined marketing message for our in-house sales team to disseminate as they increase the number of physicians using BREVAGenplus," commented Mr. Eutillio Buccilli, Chief Executive Officer of Genetic Technologies Limited. "We have been monitoring the issue of payment for a considerable period of time and have observed how other MDx companies have approached the issue and which ones have been successful in transitioning to a different collection methodology. We are confident that now is the appropriate time to make this change," concluded Mr. Buccilli.
The Company's revamped pricing strategy and numerical determination is the result of an internal review along with an industry analysis conducted by Genetic Technologies to evaluate solutions to improve the profile and ultimately, patient utilisation of BREVAGenplus. Under the patient self-pay program, BREVAGenplus will have a per test list price of USD 349.00, compared to the USD 2,795.00 which is currently presented to medical insurance providers. While the price discrepancy appears large, insurers generally pay a price much lower than list price. Patients, when confronted with the balance, often six to nine months after the test, can understandably become contentious which is typically directed at their physician. The revised BREVAGenplus price is in line with what the Company currently receives on a per test basis and does not alter the Company's view as to the commercial value of BREVAGenplus.
The review that led to the change in the pricing and billing structure for BREVAGenplus has also sharpened the Company's strategy with respect to other areas of its business. For example, the billing model designed for BREVAGenplus can also be applicable to the Company's colorectal cancer (CRC) risk assessment test which is in the latter stages of development.
http://www.marketwired.com/press-release/genetic-technologies-revamps-patient-pricing-and-billing-program-for-brevagenplusr-asx-gtg-2206734.htm
Recent GENE News
- Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering • GlobeNewswire Inc. • 04/22/2024 07:00:36 PM
- Genetic Technologies Announces $2 Million Registered Direct Offering • GlobeNewswire Inc. • 04/18/2024 04:17:51 PM
- New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- GTG to pilot GeneType in Breast Screen centers across the U.S. • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk” • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market • GlobeNewswire Inc. • 04/02/2024 12:05:00 PM
- GTG Global Collaborations and Innovation Update • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 01:00:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 01:00:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 01:00:25 PM
- Launching our most comprehensive test and expanding into new global markets • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:00:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/05/2024 01:00:16 PM
- Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 01/05/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/05/2024 05:15:09 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/28/2023 01:00:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/27/2023 01:00:13 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 12/20/2023 10:00:51 PM
- GeneType's Groundbreaking Saliva Test Transforms Early Disease Detection, Paving the Way for Personalized Wellness • GlobeNewswire Inc. • 12/14/2023 01:00:00 PM
- Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical Trial • GlobeNewswire Inc. • 10/30/2023 12:00:00 PM
- GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment • GlobeNewswire Inc. • 10/18/2023 12:30:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM